Original article The FDA has just released a briefing document for the December 12, 2024, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting titled, Considerations for Respiratory Syncytial Virus (RSV) Vaccine Safety in Pediatric Populations. The document revealed that, in July 2024, a Phase 1 trial assessing the safety, tolerability, and immunogenicity of […]